Comprehensive and Reliable Total Nucleic Acid Extraction from FFPE Samples with Covaris truXTRAC® FFPE SMART Solutions
17.4.2023 22:22:00 EEST | Business Wire | Press release
Covaris, LLC, a leader in pre-analytical sample preparation technologies, proudly unveils a comprehensive, fully automatable deparaffinization and total nucleic acid extraction workflow for formalin-fixed paraffin-embedded (FFPE) samples. Covaris truXTRAC FFPE SMART Solutions are designed for use with Covaris’ high-throughput focused-ultrasonicators and include all reagents, consumables, and accessories used in the workflow that caters to a wide range of throughput requirements.
Combining truXTRAC FFPE SMART Solutions with Covaris’ class-leading Adaptive Focused Acoustics® (AFA®) technology offers laboratories working with FFPE tissues high-quality DNA and RNA recovery in a scalable, efficient workflow that can be partially or fully automated from deparaffinization through isolation and purification steps. All this can be achieved while addressing throughput requirements and providing reliable, robust, and reproducible results. Covaris truXTRAC FFPE SMART Solutions ensure extraction and purification of DNA as well as RNA, which is otherwise difficult to process from FFPE samples. Compared to traditional workflows for FFPE samples, truXTRAC FFPE SMART Solutions do not require use of any harmful organic solvents such as xylene or hexadecane. The customized accessories included in truXTRAC FFPE SMART Solutions allow each step within the workflow to be automated and are compatible with most automated liquid handlers and on-deck or deck-adjacent instruments, such as capper/decappers, centrifuges, and Covaris’ R230 or LE220 focused-ultrasonicators.
The high-throughput focused-ultrasonicators highlighted in the workflow feature Covaris’ patented AFA technology. Using active, non-contact, mechanical deparaffinization, this technology enables complete and efficient deparaffinization without the use of harsh chemicals, resulting in recovery of high-quality DNA and RNA, while maintaining data reliability and reproducibility.
“FFPE samples contain critical information about a person’s health and hence are investigated in an array of application types,” said Annemarie Watson, CEO of Covaris, LLC. “Covaris’ truXTRAC FFPE SMART Solutions ensure high quality and yield of DNA and RNA while addressing a wide range of throughput requirements. These advantages enable researchers to generate confident, meaningful results that have impact in medical and scientific communities.”
About Covaris
Based in Woburn, MA, Covaris develops, manufactures, and markets instruments, consumables, and reagents used in pre-analytical sample preparation for genomic and proteomic analysis to help accelerate the pace of research and life science innovations. Using proprietary technologies including focused acoustic energy, Covaris’ tools achieve highly accurate and reproducible results with the goal of empowering customers to make new discoveries, develop new assays and improve bioanalytical results. Some of the non-contact applications include faster automated DNA fragmentation, cell lysis, accelerated binding partner mixing, bead resuspension, and compound formulation.
Additional information about Covaris, LLC is available at www.covaris.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005756/en/
Contact information
Media:
Kate Meola
Covaris, Inc.
+1 781-932-3959
kmeola@covaris.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Cutting-Edge Research to Industry: Focused Energy Plans Spin-Off of Sourcelight10.6.2026 12:38:00 EEST | Press release
Following its successful USD 240 million financing round, Focused Energy is continuing to systematically advance the industrialization of laser fusion as its core business. At the same time, the company plans to consolidate its activities in the field of laser-driven radiation sources into an independent entity under the name Sourcelight. With this move, Focused Energy is laying the groundwork for the industrial transfer of selected technological building blocks emerging from its laser fusion development. The spin-off demonstrates how cutting-edge research can give rise to new industry: scientific excellence is translated into industrial applications with strong value creation and growth potential. Sourcelight is intended to bring the LDRS (Laser-Driven Radiation Sources) technology developed by Focused Energy into targeted industrial applications. The technology combines laser-driven high-energy X-rays and neutrons in a single system. This enables not only high-resolution imaging, but
Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems10.6.2026 12:30:00 EEST | Press release
Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT's international market access and business development. By combining Cosylab's proven expertise in mission-critical software and complex system integration with Heron's end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality. "AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologie
GlobalFoundries and Qualinx Demonstrate First European Sovereign Manufacturing Flow for Security‑Critical Semiconductors10.6.2026 12:25:00 EEST | Press release
GlobalFoundries (GF) and Qualinx today announced the successful completion of the first fully European-based, end-to-end semiconductor manufacturing flow at GlobalFoundries’ Dresden fab on its FDX technology. The milestone demonstrates that security-critical chips for aerospace, defence and critical infrastructure can be designed, manufactured and delivered entirely within Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610196220/en/ In this partnership, Qualinx served as the launch customer with a sophisticated GNSS SoC design for secure Positioning, Navigation and Timing (PNT) applications. The QLX3xx design targets sovereign GNSS-based PNT solutions for aerospace, defence and critical infrastructures—such as resilient timing and synchronization networks and highly integrated, ultra-low-power GNSS receivers at the connected edge. GF and Qualinx Set a Benchmark for GF’s European Sovereign Manufacturing co-funded b
LTM Introduces BlueVerse™ Currency to Enable Outcome-Based Pricing in the Agentic AI Era10.6.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today introduced BlueVerse™ Currency, an AI-linked commercial model that prices enterprise work by outcomes rather than effort consumed as enterprises scale agentic AI across core processes. BlueVerse Currency brings together the full BlueVerse stack—People (expertise on demand), Accelerators (reusable assets that speed delivery), Agents (autonomous AI workforce), Platforms (orchestration layer to scale delivery), and Tokens (compute and model usage)—into a single commercial construct. It introduces outcome-linked pricing tied to measurable business results, enabling shared productivity gains so clients can capture AI-driven efficiency value. The model also supports fungible resourcing, enabling reallocation mid-contract to evolving priorities, and faster reinvestment, with savings redirected into innovation. It is underpinned by a hybrid structure with fixed and variable pricing components, supported by use-case–
Smead Capital Management Extends International Value Strategy to Global Investors Through New Fund10.6.2026 10:00:00 EEST | Press release
Smead Capital Management, a Phoenix-based investment management firm and a leader in value investing, today announced the launch of the Smead Global ex-US Value UCITS Fund designed to provide global investors with access to a product modeled after the firm’s long-standing Smead International Value Strategy. The Smead Global ex-US Value UCITS Fund is domiciled in Luxembourg. Investors can access the fund through Smead Capital Management’s website and it is available to professional and qualified investors through the fund’s transfer agent. The strategy that the Smead Global ex-US Value UCITS Fund is modeled after, the Smead International Value Strategy, has been a core contributor to Smead Capital Management’s outstanding performance for over a decade. Like all Smead products, the Global ex-US Value UCITS Fund will be built on Smead’s eight investment criteria and a disciplined, contrarian, value approach. “Many investors around the world believe non-US companies cannot produce attracti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom